Busca avançada
Ano de início
Entree


Use of methotrexate carried in lipid core nanoparticles in rats with endotoxemia: a possible new strategy for the treatment of the cardiac dysfunction in sepsis

Texto completo
Autor(es):
Lopes, Natalia de Menezes ; Guido, Maria Carolina ; Carvalho, Priscila de Oliveira ; Albuquerque, Camila Inagaki ; Jensen, Leonardo ; Debbas, Victor ; Hajjar, Ludhmila Abrahao ; Maranhao, Raul Cavalcante
Número total de Autores: 8
Tipo de documento: Artigo Científico
Fonte: Journal of Drug Targeting; v. N/A, p. 13-pg., 2025-11-06.
Resumo

Cardiac dysfunction is a major cause of death in endotoxemia. Previously, we showed that methotrexate (MTX) carried in lipid-core nanoparticles (LDE) can modulate immune response and increase myocardial angiogenesis. The aim was to test the effects of LDE-methotrexate (LDEMTX) in rats with endotoxemia. Twenty male rats received I.P. injections of lipopolysaccharides (LPS, 10 mg/kg twice, 24h interval) and were allocated to 3 groups: LPS-LDEMTX, injected I.P. with 1 mg/kg MTX associated with LDE; LPS-MTX with conventional MTX (1 mg/kg, I.P.); LPS-LDE, injected with LDE only. A control group (CT) without endotoxemia was included. Echocardiography was performed 72h after endotoxemia induction. Animals were euthanized for analysis. LPS-LDE developed LV diastolic dysfunction, which was prevented in both LPS-LDEMTX and LPS-MTX groups. LPS-LDEMTX, but not LPS-MTX, developed compensatory LV hypertrophy. In LPS-LDEMTX, cellular hypoxia was lower, and angiogenesis was higher than in LPS-MTX and LPS-LDE, indicated by expression of hypoxia-inducible factor 1 alpha, vascular endothelial growth factor and angiopoietin 1/2, respectively. Intracellular adenosine was increased in LPS-LDEMTX, with higher adenosine receptor expression. LPS-MTX but not LPS-LDEMTX showed hepatic toxicity. In conclusion, both LDEMTX and MTX prevented diastolic dysfunction in endotoxemia, but LDEMTX was further capable of improving several other parameters and had no toxicity. (AU)

Processo FAPESP: 20/16215-0 - Nanopartículas lipídicas (LDE) como veículos de quimioterápicos: novo paradigma para a terapêutica médica
Beneficiário:Raul Cavalcante Maranhao
Modalidade de apoio: Auxílio à Pesquisa - Temático